BAJAJ BROKING

Notification
No new Notification messages
Tankup Engineers IPO is Open!
Apply for the Tankup Engineers IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

11703

539523

ALKEM

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

ALKEM LABORATORIES LTD. performance

Today’s low

Today’s high

₹ 5068.40 ₹ 5238.00
₹ 5156.60

52 week low

52 week high

₹ 4407.05 ₹ 6439.90
₹ 5156.60

Open Price

₹ 5238.00

Prev. Close

₹ 5201.20

Volume (Shares)

4546.00

Total traded value

₹ 234.41

Upper Circuit

₹ 5721.30

Lower Circuit

₹ 4681.10

info

ALKEM LABORATORIES LTD. Share Price Update

As of the latest trading session, ALKEM LABORATORIES LTD. share price is currently at ₹ 5072.6, which is down by -128.60 from its previous closing. Today, the stock has fluctuated between ₹ 5068.40 and ₹ 5238.00. Over the past year, ALKEM LABORATORIES LTD. has achieved a return of 10.17 %. In the last month alone, the return has been 2.94 %. Read More...

ALKEM LABORATORIES LTD. fundamentals


  • Market cap (Cr)

    60,650.54

  • P/E Ratio (TTM)

    26.80

  • Beta

    0.57

  • Book Value / share

    984.45

  • Return on equity

    17.56%

  • EPS (TTM)

    187.04

  • Dividend yield

    0.77%

  • Net profit/quarter (Cr)

    723.12

info icon alternate text
  • Market cap (Cr)

    60,571.63

  • P/E Ratio (TTM)

    26.80

  • Beta

    0.55

  • Book Value / share

    984.45

  • Return on equity

    17.56%

  • EPS (TTM)

    187.04

  • Dividend yield

    0.77%

  • Net profit/quarter (Cr)

    723.12

info icon alternate text

ALKEM LABORATORIES LTD. Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars DEC 2024 (Values in Cr)
Revenue 2286.83
Operating Expense 1717.61
Net Profit 723.12
Net Profit Margin (%) 31.62
Earnings Per Share (EPS) 60.48
EBITDA 827.01
Effective Tax Rate (%) 8.41
Particulars SEP 2024 (Values in Cr)
Revenue 2354.72
Operating Expense 1792.91
Net Profit 697.58
Net Profit Margin (%) 29.62
Earnings Per Share (EPS) 58.34
EBITDA 760.47
Effective Tax Rate (%) 5.88
Particulars JUN 2024 (Values in Cr)
Revenue 2500.10
Operating Expense 1965.26
Net Profit 583.25
Net Profit Margin (%) 23.32
Earnings Per Share (EPS) 48.78
EBITDA 726.73
Effective Tax Rate (%) 9.00
Particulars MAR 2024 (Values in Cr)
Revenue 2365.37
Operating Expense 2047.63
Net Profit 324.97
Net Profit Margin (%) 13.73
Earnings Per Share (EPS) 27.18
EBITDA 478.78
Effective Tax Rate (%) 16.46
Particulars DEC 2023 (Values in Cr)
Revenue 2008.88
Operating Expense 1594.03
Net Profit 504.23
Net Profit Margin (%) 25.10
Earnings Per Share (EPS) 42.17
EBITDA 536.69
Effective Tax Rate (%) 0.84
Particulars MAR 2024 (Values in Cr)
Revenue 7963.85
Operating Expense 6611.88
Net Profit 1747.15
Net Profit Margin (%) 21.93
Earnings Per Share (EPS) 146.13
EBITDA 1913.34
Effective Tax Rate (%) 2.10
Particulars MAR 2023 (Values in Cr)
Revenue 9054.55
Operating Expense 7993.84
Net Profit 1134.47
Net Profit Margin (%) 12.52
Earnings Per Share (EPS) 94.88
EBITDA 1643.24
Effective Tax Rate (%) 14.50
Particulars MAR 2022 (Values in Cr)
Revenue 8829.81
Operating Expense 7276.33
Net Profit 1541.25
Net Profit Margin (%) 17.45
Earnings Per Share (EPS) 128.90
EBITDA 2010.25
Effective Tax Rate (%) 12.09
Particulars MAR 2021 (Values in Cr)
Revenue 7219.68
Operating Expense 5512.61
Net Profit 1685.08
Net Profit Margin (%) 23.34
Earnings Per Share (EPS) 140.93
EBITDA 2126.16
Effective Tax Rate (%) 10.57
Particulars MAR 2020 (Values in Cr)
Revenue 6677.08
Operating Expense 5434.98
Net Profit 1264.42
Net Profit Margin (%) 18.93
Earnings Per Share (EPS) 105.75
EBITDA 1563.62
Effective Tax Rate (%) 5.50
Particulars MAR 2024 (Values in Cr)
Book Value / Share 862.57
ROE % 18.72
ROCE % 18.29
Total Debt to Total Equity 0.15
EBITDA Margin 19.22
Particulars MAR 2023 (Values in Cr)
Book Value / Share 756.61
ROE % 11.39
ROCE % 12.48
Total Debt to Total Equity 0.23
EBITDA Margin 14.85
Particulars MAR 2022 (Values in Cr)
Book Value / Share 722.53
ROE % 20.98
ROCE % 18.00
Total Debt to Total Equity 0.28
EBITDA Margin 20.69
Particulars MAR 2021 (Values in Cr)
Book Value / Share 617.04
ROE % 23.90
ROCE % 21.70
Total Debt to Total Equity 0.25
EBITDA Margin 24.54
Particulars MAR 2020 (Values in Cr)
Book Value / Share 515.32
ROE % 19.82
ROCE % 18.07
Total Debt to Total Equity 0.22
EBITDA Margin 18.91
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 1579.35
Total Assets 15574.90
Total Liabilities 15574.90
Total Equity 10714.40
Share Outstanding 119565000
Price to Book Ratio 5.60
Return on Assets (%) 11.52
Return on Capital (%) 15.05
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 2616.89
Total Assets 13756.65
Total Liabilities 13756.65
Total Equity 9435.00
Share Outstanding 119565000
Price to Book Ratio 4.34
Return on Assets (%) 7.15
Return on Capital (%) 9.16
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 2578.58
Total Assets 14069.19
Total Liabilities 14069.19
Total Equity 8847.33
Share Outstanding 119565000
Price to Book Ratio 4.95
Return on Assets (%) 11.69
Return on Capital (%) 14.4
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 1990.45
Total Assets 11519.26
Total Liabilities 11519.26
Total Equity 7558.01
Share Outstanding 119565000
Price to Book Ratio 4.35
Return on Assets (%) 13.75
Return on Capital (%) 17.12
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 1092.21
Total Assets 9945.54
Total Liabilities 9945.54
Total Equity 6308.97
Share Outstanding 119565000
Price to Book Ratio 4.43
Return on Assets (%) 11.33
Return on Capital (%) 14.29
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 1065.85
Total Assets 14037.80
Total Liabilities 14037.80
Total Equity 10554.61
Share Outstanding 119565000
Price to Book Ratio 5.60
Return on Assets (%) 12.44
Return on Capital (%) 15.18
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 2163.87
Total Assets 12731.22
Total Liabilities 12731.22
Total Equity 9349.85
Share Outstanding 119565000
Price to Book Ratio 4.34
Return on Assets (%) 8.91
Return on Capital (%) 10.83
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 2297.21
Total Assets 13169.17
Total Liabilities 13169.17
Total Equity 8743.66
Share Outstanding 119565000
Price to Book Ratio 4.95
Return on Assets (%) 11.70
Return on Capital (%) 14.03
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 1673.36
Total Assets 10772.73
Total Liabilities 10772.73
Total Equity 7625.75
Share Outstanding 119565000
Price to Book Ratio 4.35
Return on Assets (%) 15.64
Return on Capital (%) 18.81
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 765.61
Total Assets 9105.83
Total Liabilities 9105.83
Total Equity 6280.44
Share Outstanding 119565000
Price to Book Ratio 4.43
Return on Assets (%) 13.88
Return on Capital (%) 16.88
Particulars MAR 2024 (Values in Cr)
Net Income 2023.13
Cash from Operations 2355.01
Cash from Investing -1008.50
Cash from Financing -1145.01
Net change in Cash -205.44
Free Cash Flow 2614.30
Particulars MAR 2023 (Values in Cr)
Net Income 1304.77
Cash from Operations 1955.89
Cash from Investing 112.84
Cash from Financing -1760.82
Net change in Cash 34.52
Free Cash Flow 2188.80
Particulars MAR 2022 (Values in Cr)
Net Income 1844.28
Cash from Operations 1507.92
Cash from Investing -1435.13
Cash from Financing 379.57
Net change in Cash 55.46
Free Cash Flow 1846.80
Particulars MAR 2021 (Values in Cr)
Net Income 1842.10
Cash from Operations 1665.58
Cash from Investing -998.54
Cash from Financing -271.75
Net change in Cash -5.39
Free Cash Flow 1860.49
Particulars MAR 2020 (Values in Cr)
Net Income 1259.79
Cash from Operations 868.46
Cash from Investing -741.35
Cash from Financing 79.15
Net change in Cash -77.12
Free Cash Flow 1231.55
Particulars MAR 2024 (Values in Cr)
Net Income 1881.03
Cash from Operations 2039.39
Cash from Investing -865.60
Cash from Financing -959.04
Net change in Cash -138.08
Free Cash Flow 2146.07
Particulars MAR 2023 (Values in Cr)
Net Income 1326.99
Cash from Operations 1661.58
Cash from Investing 197.04
Cash from Financing -1711.27
Net change in Cash -76.81
Free Cash Flow 1803.36
Particulars MAR 2022 (Values in Cr)
Net Income 1753.37
Cash from Operations 1634.19
Cash from Investing -1669.33
Cash from Financing 436.59
Net change in Cash 66.60
Free Cash Flow 1879.06
Particulars MAR 2021 (Values in Cr)
Net Income 1884.30
Cash from Operations 1645.78
Cash from Investing -1120.99
Cash from Financing -208.96
Net change in Cash -5.47
Free Cash Flow 1776.59
Particulars MAR 2020 (Values in Cr)
Net Income 1338.08
Cash from Operations 915.72
Cash from Investing -995.17
Cash from Financing 172.64
Net change in Cash -140.75
Free Cash Flow 1197.81
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 39.43 21.20 2.15 302.17 34.11 / 77.70
BLISS GVS PHARMA LTD 126.30 16.55 1.31 1330.83 92.25 / 184.95
CIPLA LTD 1551.30 25.11 4.41 125285.64 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 289.65 24.00 2.93 852.47 145.00 / 449.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 39.43 23.75 6.70 302.17 34.11 / 77.70
AMRUTAJAN HEALTH LTD 672.50 39.42 6.52 1944.24 548.05 / 861.40
ASTRAZENECA PHARMA IND LT 8961.95 133.66 32.97 22404.88 5000.00 / 9199.00
BLISS GVS PHARMA LTD 126.30 16.40 1.29 1330.83 92.25 / 184.95

ALKEM LABORATORIES LTD. Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
5156.60 -0.85 redarrow
red-green-graph indicator
2 Bearish
14 Bullish
  • 5 Days 5103.60
  • 26 Days 4939.10
  • 10 Days 5027.50
  • 50 Days 4946.10
  • 12 Days 5008.50
  • 100 Days 5080.80
  • 20 Days 4958.80
  • 200 Days 5162.80
5167.83 PIVOT

First Support

5085.17

First Resistance

5315.67

Second Support

4937.33

Second Resistance

5398.33

Third Support

4854.67

Third Resistance

5546.17

RSI

65.98

ADX

19.72

MACD

69.34

Williams % R

-14.23

Commodity Channel Index (CCI)

202.36

Date

2025-04-24

Week

39613.00

Same Day

57162.00

Month

47380.00

1 Year

0.57

3 Year

0.52

Over 1 Month

2.94%

down

Over 1 Year

10.17%

down

Over 3 Months

3.55%

down

Over 3 Years

16.24%

down

Over 6 Months

-12.74%

down

Over 5 Years

13.72%

down

Invest with Confidence

Left Arrow
MTF boost
Buy Now. Pay Later

Boost your capital upto 5 X

img
IPO boost
Invest in IPOs
They give good returns
img
Right Arrow

ALKEM LABORATORIES LTD. shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
16.04%
Promoter Holdings
55.12%
FII
9.4%
DII
19.41%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Sarandhar Singh* (please Refer Notes) 2.3214088E7 (19.42%) Shareholding of Promoter and Promoter Group
Basudeo Narain Singh 8695360.0 (7.27%) Shareholding of Promoter and Promoter Group
Mritunjay Kumar Singh 7682000.0 (6.42%) Shareholding of Promoter and Promoter Group
Madhurima Singh& (please Refer Notes) 7393939.0 (6.18%) Shareholding of Promoter and Promoter Group
Icici Prudential Multi-asset Fund 4914737.0 (4.11%) Public Shareholding
Sbi Large & Midcap Fund 3560792.0 (2.98%) Public Shareholding
Kishor Kumar Singh 3373312.0 (2.82%) Public Shareholding
Madhurima Singh@ (please Refer Notes) 3092875.0 (2.59%) Shareholding of Promoter and Promoter Group
Jayanti Sinha 2938220.0 (2.46%) Shareholding of Promoter and Promoter Group
Alok Kumar 2764719.0 (2.31%) Public Shareholding
Ashok Kumar 2688000.0 (2.25%) Public Shareholding
Seema Singh 2579045.0 (2.16%) Shareholding of Promoter and Promoter Group
Deepak Kumar Singh 2492283.0 (2.08%) Public Shareholding
Archana Singh 2394050.0 (2.0%) Shareholding of Promoter and Promoter Group
Dsp Midcap Fund 1861905.0 (1.56%) Public Shareholding
Rajesh Kumar 1684535.0 (1.41%) Public Shareholding
Hdfc Life Insurance Company Limited 1641605.0 (1.37%) Public Shareholding
Nippon Life India Trustee Ltd-a/c Nippon India Growth Fund 1621570.0 (1.36%) Public Shareholding
Rajeev Ranjan 1485342.0 (1.24%) Public Shareholding
Government Pension Fund Global 1299930.0 (1.09%) Public Shareholding
Meghna Singh 1208650.0 (1.01%) Shareholding of Promoter and Promoter Group
Divya Singh & (please Refer Notes) 1208971.0 (1.01%) Shareholding of Promoter and Promoter Group
Aniruddha Singh & (please Refer Notes) 1208971.0 (1.01%) Shareholding of Promoter and Promoter Group
Shrey Shree Anant Singh 1195650.0 (1.0%) Shareholding of Promoter and Promoter Group
Shikhar Raj 550000.0 (0.46%) Shareholding of Promoter and Promoter Group
Satyam Sinha 550000.0 (0.46%) Shareholding of Promoter and Promoter Group
Sakshi Sinha 550000.0 (0.46%) Shareholding of Promoter and Promoter Group
Sadhika Raj 550000.0 (0.46%) Shareholding of Promoter and Promoter Group
Raj Kumar Singh 538038.0 (0.45%) Shareholding of Promoter and Promoter Group
Srinivas Singh # (please Refer Notes) 102695.0 (0.09%) Shareholding of Promoter and Promoter Group
Manju Singh # (please Refer Notes) 100517.0 (0.08%) Shareholding of Promoter and Promoter Group
Sarandhar Singh # (please Refer Notes) 79800.0 (0.07%) Shareholding of Promoter and Promoter Group
Satish Kumar Singh # (please Refer Notes) 72430.0 (0.06%) Shareholding of Promoter and Promoter Group
Inderjit Kaur Arora # (please Refer Notes) 7800.0 (0.01%) Shareholding of Promoter and Promoter Group
Sarvesh Singh # (please Refer Notes) 1.0 (0.0%) Shareholding of Promoter and Promoter Group
Premlata Singh # (please Refer Notes) 1.0 (0.0%) Shareholding of Promoter and Promoter Group
Annapurna Singh # (please Refer Notes) 1.0 (0.0%) Shareholding of Promoter and Promoter Group
Sandeep Singh # (please Refer Notes) 7.0 (0.0%) Shareholding of Promoter and Promoter Group

News

Left Arrow
Right Arrow

ALKEM LABORATORIES LTD. corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
16 Feb 2024 35.0 Interim 17 Feb 2024 Equity shares
10 Aug 2023 10.0 Final 10 Aug 2023 Equity shares
17 Feb 2023 15.0 Interim 18 Feb 2023 Equity shares
17 Feb 2023 25.0 Special 18 Feb 2023 Equity shares
08 Aug 2022 4.0 Final 10 Aug 2022 Equity shares
10 Feb 2022 30.0 Interim 12 Feb 2022 Equity shares
09 Aug 2021 5.0 Final 10 Aug 2021 Equity shares
11 Feb 2021 25.0 Interim 13 Feb 2021 Equity shares
10 Aug 2020 3.0 Final 11 Aug 2020 Equity shares
13 Feb 2020 22.0 Interim 15 Feb 2020 Equity shares
19 Aug 2019 8.0 Final 20 Aug 2019 Equity shares
15 Feb 2019 8.0 Interim 18 Feb 2019 Equity shares
23 Aug 2018 7.0 Final 24 Aug 2018 Equity shares
16 Feb 2018 6.0 Interim 20 Feb 2018 Equity shares
31 Aug 2017 9.0 Final 01 Sep 2017 Equity shares
23 Nov 2016 6.0 Interim 24 Nov 2016 Equity shares
18 Mar 2016 9.7 Interim 2 21 Mar 2016 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
16 Feb 2024 35.0 Interim 17 Feb 2024 Equity shares
10 Aug 2023 10.0 Final 10 Aug 2023 Equity shares
17 Feb 2023 15.0 Interim 18 Feb 2023 Equity shares
17 Feb 2023 25.0 Special 18 Feb 2023 Equity shares
08 Aug 2022 4.0 Final 10 Aug 2022 Equity shares
10 Feb 2022 30.0 Interim 12 Feb 2022 Equity shares
09 Aug 2021 5.0 Final 10 Aug 2021 Equity shares
11 Feb 2021 25.0 Interim 13 Feb 2021 Equity shares
10 Aug 2020 3.0 Final 11 Aug 2020 Equity shares
13 Feb 2020 22.0 Interim 15 Feb 2020 Equity shares
19 Aug 2019 8.0 Final 20 Aug 2019 Equity shares
15 Feb 2019 8.0 Interim 18 Feb 2019 Equity shares
23 Aug 2018 7.0 Final 24 Aug 2018 Equity shares
16 Feb 2018 6.0 Interim 20 Feb 2018 Equity shares
31 Aug 2017 9.0 Final 01 Sep 2017 Equity shares
23 Nov 2016 6.0 Interim 24 Nov 2016 Equity shares
18 Mar 2016 9.7 Interim 2 21 Mar 2016 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]

ALKEM LABORATORIES LTD. Share Price

Headquartered in Mumbai, India, Alkem Laboratories Limited is a leading Indian pharmaceutical company with global operations. The company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals, which it markets in India and international markets. With a portfolio of more than 800 brands in India, Alkem is ranked the fifth largest pharmaceutical company in India in terms of domestic sales. The company also has presence in more than 40 international markets, with the United States being its key focus market.

Alkem Laboratories Limited was incorporated as a private limited company on August 8, 1973 in Patna and subsequently became a deemed public limited company on October 26, 1988. Pursuant to Company passing a resolution under section 21 of Companies Act, 1956 and upon issuance of a fresh certificate of incorporation consequent on change of name dated August 21, 2001, the name of the Company was changed to 'Alkem Laboratories Limited' with effect from October 26, 1988.

In 1978, the company established its first plant at Taloja Maharashtra. In 1992, the company established its manufacturing facility in Mandwa, Maharashtra, which was later converted into an API facility in 2005. In 2003, the company set up a research and development facility for ANDA development at Taloja, Maharashtra.

During the year 2006, the company's anti-infective drug Taxim became the first anti-infective drug in the Indian pharmaceutical industry to cross Rs 100 crore in terms of domestic sales in India. In 2007, the company filed its first ANDA in the US for the drug Amlodipine. In 2009, the company received first ANDA approval in US for Amlodipine. Also during the year, the company acquired Pharmacor Pty Ltd., a generic pharma company in Australia.

In 2010, Alkem Laboratories acquired Ascend Laboratories, a generic marketing company in the US. In 2011, the company acquired Enzene, a company engaged in the development of biosimilars in India. In 2012, the company acquired an API manufacturing facility in the US.

In 2014, the company acquired the 'Clindac-A' brand in India from Galderma S.A. Also during the year, Clavam crossed Rs 200 crore mark in terms of domestic sales in India. In 2015, the company acquired a formulation manufacturing facility in the US.

During the FY2015,the company has done the stock split reduced the face value of equity share from Rs 10 to Rs 2 and also approved and allotted 59782500 bonus shares in the ratio of 1:1.

On 23 December 2015, Alkem Laboratories successfully completed an Initial Public Offering (IPO) with its equity shares listed on the Bombay Stock Exchange Limited and the National Stock Exchange of India Limited.

On 10 May 2016, Alkem Laboratories announced that the Competition Appellate Tribunal (COMPAT) has passed an order dated 10 May2016 setting aside the penalty of Rs 74.63 crore imposed on the company by the Competition Commission of India (CCI) in its order dated 1 December 2015.

On 7 June 2016, Alkem Laboratories announced the closure of the inspection by the United Kingdom - The Medicines and Healthcare Products Regulatory Agency (UK-MHRA) for its Bioequivalence facility at Taloja, Maharashtra, India. The facility stands UK-MHRA compliant.

On 11 August 2016, Alkem Laboratories announced that the USFDA inspected the company's Bioequivalence facility at Taloja, Maharashtra, India from 1 August to 10 August 2016. At the end of the inspection, there were no 483s issued by the USFDA.

On 28 October 2016, Alkem Laboratories announced that the USFDA conducted a Bio-analytical inspection at the company's manufacturing facility located at Daman, India from 24 October to 28 October 2016. The inspection has been cleared successfully without any 483 observations. This inspection was based on an ANDA filed by the company.

On 7 February 2017, Alkem Laboratories announced that it has entered into an alliance with Haw Par India Pvt Ltd., a wholly owned subsidiary of Haw Par Healthcare Ltd., Singapore to exclusively market, sell and distribute Tiger Balm range of products in India. Tiger Balm products will be promoted by Alkem Healthcare, an Over the Counter (OTC) division of Alkem. Tiger Balm range of products is an internationally known remedy for headaches, upper respiratory congestions, rheumatic or arthritic pains and muscular sprains. Its unique blend of herbal ingredients, derived from an ancient Chinese source, has been proven effective for nearly 100 years and is trusted by millions of people in more than 100 countries.

On 29 March 2017, Alkem Laboratories announced that the USFDA has issued an Establishment Inspection Report (EIR) for its Ankaleshwar API facility which was inspected in December 2016. The inspection has now been closed by the USFDA. The USFDA had inspected the Ankaleshwar API manufacturing facility from 5 to 9 December 2016 and had issued Form 483 with three observations. Post this, the company had submitted a detailed corrective and preventive action plan (CAPA) to the regulator within the stipulated timelines. The USFDA has reviewed the CAPA and has found them acceptable.

On 10 January 2018, Alkem Laboratories announced the closure of USFDA inspection at its Baddi facility in Himachal Pradesh.

On 28 March 2018, Alkem Laboratories informed the stock exchanges that the USFDA conducted an inspection at the company's manufacturing facility located at Amaliya, Daman, India from 19 March 2018 to 27 March 2018. Post the inspection, the company has received a Form 483 with thirteen observations. The company said it will put together a detailed response with adequate corrective and preventive measures to address the USFDA observations within the timeline stipulated by the USFDA. The USFDA also conducted an inspection at the company's manufacturing facility located at St. Louis, USA from 12 March 2018 to 16 March 2018. In response to the one Form 483 observation issued by the USFDA, the company has submitted a detailed corrective and preventive action plan (CAPA) plan to the regulator within the stipulated timelines.

During the FY2019, the wholly owned subsidiary of the Company Alkem Laboratories (NIG) Limited was dissolved w.e.f. 06th May, 2018 pursuant to voluntary winding up. As on 31 March 2019,the company had 20 subsidiary companies under its roof.

In FY 2018-19, the company invested Rs 4.62 billion or 6.3% of total revenues in R&D, compared to 5.7% in FY 2017-18. The company filed 23 ANDAs during the year and received 21 approvals, which includes 6 tentative approvals. The company have a fairly strong product pipeline of 127 ANDAs (as on 31st March, 2019) already filed with the USFDA, with over half of them yet to be commercialised.

The Company has also made investments in the biosimilar segment through its subsidiary Enzene Biosciences - a biotech-focussed company located in Pune (Maharashtra, India).

The company bagged Express Pharma Excellence Award at Pharma CXO Summit 2019.

During the FY2020, a new company named Ascend Laboratories SAS was incorporated on 04th June, 2019 as a wholly owned subsidiary of the Company in Colombia. Also on 08th April, 2020, a new company named S&B Pharma LLC had been incorporated as a Step down subsidiary of the Company in USA. As on 31 March 2020,the company had 21 subsidiary companies under its roof.

During the year 2019-20, the company invested Rs 4,726 million or 5.7% of total revenues in R&D, as against Rs 4,622 million in FY 2018-19. The company filed 18 ANDAs during the year and received 22 ANDA approvals which includes 6 tentative approvals. Alkem now has a total of 144 ANDAs (as on 31st March, 2020) filed with the USFDA and 89 approvals.

During the quarter ended 30 June 2020, the Company filed 4 abbreviated new drug applications (ANDAs) with the US FDA and received 2 approvals (including 1 tentative approval). As on June 30, 2020, the Company filed a total of 146 ANDAs and 2 new drug applications (NDA) with the USFDA. Of these, it has received approvals for 88 ANDAs (including 13 tentative approvals) and 2 NDAs.

During the quarter ended 30 September 2020, the Company filed 1 abbreviated new drug applications (ANDAs) with the US FDA and received 4 approvals (including 1 tentative approval). As on September 30, 2020, the Company has filed a total of 147 ANDAs and 2 new drug applications (NDA) with the USFDA of which it has received approvals for 91 ANDAs (including 13 tentative approvals) and 2 NOA.

During the quarter ended 31 December 2020, the Company received 10 approvals (including 2 tentative approvals) from the USFDA. As on December 31, 2020, the Company has filed a total of 147 ANDAs and 2 new drug application (NDA) with the US FDA of which it has received approvals for 100 ANDAs (including 14 tentative approvals) and 2 NOA.

In FY'20, Company started new formulation manufacturing facility in Indore and a new biologic / biosimilar manufacturing facility in Pune. S&B Pharma LLC has been incorporated as a step down subsidiary of the Company in USA on 08th April, 2020, and on 12th June, 2020, the Company acquired M/s Connect 2 Clinic Private Limited, a Company incorporated under the Companies Act, 2013.

For business synergies, ease of administration and simplification in the organization structure for its business operations in USA market, the Company's Board of Directors at its meeting held on 25 May 2021 has approved the proposed plan for restructuring of the USA business operations by bringing both the subsidiary entities namely, S & B Pharma Inc, USA ('S & B') (engaged in manufacturing of pharmaceutical products and contract research) and The PharmaNetwork LLC, USA ('TPNC') (engaged in sales & marketing of pharmaceuticals products) under a single umbrella by removing intermediary holding company S & B Holdings BV, Netherlands ('S & B BV'). This Board approved restructuring is subject to necessary statutory and regulatory approvals.

During the quarter ended 31 March 2021, the Company filed 4 abbreviated new drug applications (ANDAs) with the US FDA and received 10 approvals (including 3 tentative approvals). During the FY2021,the Company filed 9 ANDAs with the US FDA and received 25 approvals (including 6 tentative approvals). As on March 31, 2021, the Company filed a total of 150 ANDAs and 2 new drug applications (NDA) with the US FDA. Of these, it has received approvals for 108 ANDAs (including 16 tentative approvals) and 2 NDAs.

In FY'21, First product was launched from Enzene Biosciences in India. The Company ventured into respiratory segment in India with the launch of Pulmocare division.

Connect2Clinic, the Company's online platform for participating medical professionals and healthcare staff to connect with their
patients, witnessed a significant surge in activity. In FY'21-22, Connect2Clinic crossed an important milestone of 1 lakh doctor consultations and is growing fast to become a preferred end-to-end OPD management platform in India.

During the year 2022-23, Enzene Inc., was incorporated as a step down subsidiary of the Company in USA on 26th May, 2022 and Pharmacor Limited, incorporated as a step down subsidiary of the Company in New Zealand on 01st June, 2022. The Company launched Adalimumab in the domestic markets in 2023. A new Marketing and Sales division, Metanext was launched in the Chronic segment.

In 2023-24, Company launched world's first biosimilar of Cetuximab, namely Cetuxa. It ventured into the trade generics segment. Alkem Medtech Private Limited, got incorporated on March 27, 2024, in India, as a wholly owned subsidiary of the company;

Parent organization Indian Private
NSE symbol ALKEM
Founded 1973
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Share Price of Alkem Laboratories Ltd?

Answer Field

The share price of Alkem Laboratories Ltd for NSE is ₹ 5072.6 and for BSE is ₹ 5066.

What is the Market Cap of Alkem Laboratories Ltd?

Answer Field

The market cap of Alkem Laboratories Ltd for NSE is ₹ 6,06,50.54 Cr. and for BSE is ₹ 6,05,71.63 Cr. as of now.

What is the 52 Week High and Low of Alkem Laboratories Ltd?

Answer Field

The 52 Week High and Low of Alkem Laboratories Ltd for NSE is ₹ 6439.90 and ₹ 4407.05 and for BSE is ₹ 6440.00 and ₹ 4409.90.

How to Buy Alkem Laboratories Ltd share?

Answer Field

You can trade in Alkem Laboratories Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Alkem Laboratories Ltd?

Answer Field

The 1 year returns on the stock has been 10.17%.

What is the Current Share Price of Alkem Laboratories Ltd?

Answer Field

Alkem Laboratories Ltd share price is for NSE ₹ 5072.6 & for BSE ₹ 5066 as on Apr 25 2025 09:58 AM.

What is the Market Cap of Alkem Laboratories Ltd Share?

Answer Field

The market cap of Alkem Laboratories Ltd for NSE ₹ 6,06,50.54 & for BSE ₹ 6,05,71.63 as on Apr 25 2025 09:58 AM.

What is the P/E Ratio of Alkem Laboratories Ltd Share?

Answer Field

As on Apr 25 2025 09:58 AM the price-to-earnings (PE) ratio for Alkem Laboratories Ltd share is 26.80.

What is the PB ratio of Alkem Laboratories Ltd Share?

Answer Field

As on Apr 25 2025 09:58 AM, the price-to-book (PB) ratio for Alkem Laboratories Ltd share is 984.45.

How to Buy Alkem Laboratories Ltd Share?

Answer Field

You can trade in Alkem Laboratories Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Alkem Laboratories Ltd Share on Bajaj Broking App?

Answer Field

To buy Alkem Laboratories Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Alkem Laboratories Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|